Year: 2017
BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB’s 8th Annual Nordic Healthcare Conference
December 14, 2017
Six ph II clinical trials ongoing with first-in-class highly selective AXL inhibitor BGB324. Monotherapy data…
Read MoreBerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting
December 11, 2017
35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two CRi and five PR…
Read MoreBerGenBio ASA: Results for the Third Quarter 2017
November 17, 2017
Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing…
Read MoreBerGenBio to present at Jefferies 2017 London Healthcare Conference
November 16, 2017
Bergen, Norway, 16 November 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium
November 14, 2017
Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast
November 10, 2017
Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)